Evidence map›Paper›PMID 34606754›Full record

ArticleThe American journal of the medical sciences2022

Prevalence, Distribution and IgG Antibody Levels Associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Health-System and Community-Based Employees and Patients.

Edmond K Kabagambe, Cruz Velasco-Gonzalez, Marcia B Henry, Dan Fort, Qingli Wu, Gregory Sossaman, Yvens Laborde, Eboni Price-Haywood, W Mark Roberts, Leonardo Seoane

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of the medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Edmond K KabagambeDivision of Academics, Ochsner Health, New Orleans, LA, USA; Ochsner Center for Outcomes Research, Division of Academics, Ochsner Health, New Orleans, LA, USA. Electronic address: edmond.kabagambe@ochsner.org.
Cruz Velasco-GonzalezOchsner Center for Outcomes Research, Division of Academics, Ochsner Health, New Orleans, LA, USA.
Marcia B HenryDivision of Academics, Ochsner Health, New Orleans, LA, USA.
Dan FortOchsner Center for Outcomes Research, Division of Academics, Ochsner Health, New Orleans, LA, USA.
Qingli WuDepartment of Pathology, Ochsner Health, New Orleans, LA, USA.
Gregory SossamanDepartment of Pathology, Ochsner Health, New Orleans, LA, USA.
Yvens LabordeGlobal Health Education, Ochsner Health, New Orleans, LA, USA.
Eboni Price-HaywoodDivision of Academics, Ochsner Health, New Orleans, LA, USA; Ochsner Center for Outcomes Research, Division of Academics, Ochsner Health, New Orleans, LA, USA; University of Queensland Ochsner Clinical School, Ochsner Health, New Orleans, LA, USA.
W Mark RobertsDivision of Academics, Ochsner Health, New Orleans, LA, USA.
Leonardo SeoaneDivision of Academics, Ochsner Health, New Orleans, LA, USA; University of Queensland Ochsner Clinical School, Ochsner Health, New Orleans, LA, USA.
Ochsner Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing the high morbidity and mortality due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections in New Orleans, Louisiana, we sought to assess progress toward herd immunity.

methodsOchsner Health employees and patients who volunteered for Abbott SARS-CoV-2 immunoglobulin G (IgG) antibody test between March 1 and May 1, 2020 were included. We estimated IgG prevalence and used logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) for variables associated with IgG test status.

resultsOf the 13,343 participants with IgG test results, 78.6% were women, 70.6% were non-Hispanic White, 21.1% non-Hispanic Black, 2.9% Hispanic Americans and 5.4% belonged to other races. Overall, 7.99% (95% CI: 7.53-8.45%) of the participants tested IgG positive. In age-, sex- and body mass index (BMI)-adjusted analyses, non-Hispanic Blacks were 2.7-times more likely to test positive than non-Hispanic Whites (OR=2.72; 95% CI: 2.33-3.19). Corresponding ORs (95% CIs) were 1.29 (0.84-1.99) for Hispanic Americans and 1.22 (0.85-1.75) for Other race/ethnicities. Compared to participants in administrative occupations, physician assistants (OR=7.14; 95% CI: 1.72-29.6) and therapists (OR=4.74; 95% CI: 1.49-15.03) were significantly more likely to have IgG antibodies while the association among nurses was not significant (OR=2.35; 95% CI: 0.96-5.77). Relative to 1.40, the test threshold for positivity, our measurements indicate a strong immune response (5.38±1.69), especially among those with a higher BMI.

conclusionsSARS-COV-2 IgG antibodies were prevalent only in 8% of the participants. IgG prevalence was highest among non-Hispanic Blacks and participants with higher BMI but was lower among older participants.

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin GSARS-CoV-2COVID-19 Serological TestingFemaleHealth PersonnelHumansMaleNew OrleansPatientsPrevalenceAntibodies, ViralImmunoglobulin GCOVID-19IgG antibodiesNon-Hispanic BlacksPrevalenceSARS-COV-2

Identifiers

PMID34606754
PMCPMC8485713
OpenAlexW3204645015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.